Clinical Insights Surrounding CheckMate 9ER Updates and Use of Nivolumab Plus Cabozantinib in ccRCC
Toni Choueiri, MD, and Rohit Gosain, MD summarize the implications of the CheckMate 9ER 3-year follow-up data and highlight remaining questions and unmet needs in the RCC landscape.
A Post-hoc Analysis of CheckMate 9ER Data and Study Conclusions
A brief overview of post-hoc data from the CheckMate 9ER trial examining baseline characteristics and time to subsequent therapy in patients who received at least two years of nivolumab treatment, followed by study conclusions.
Adverse Events Following Use of Nivolumab Plus Cabozantinib in Patients With Advanced ccRCC
Panelists continue to discuss long-term follow-up data from the CheckMate 9ER trial, focusing on treatment-related adverse events seen in patients with ccRCC treated with nivolumab plus cabozantinib.
CheckMate 9ER: Progression-free Survival, Overall Survival, and Objective
Two subject matter experts discuss survival and response data from the CheckMate 9ER trial comparing combination nivolumab/cabozantinib to sunitinib in patients with advanced ccRCC.
A Closer Look at Study Design and Patient Demographics from the CheckMate 9ER Trial
Drs Choueiri and Gosain review study design, patient demographics, and clinical characteristics from the CheckMate 9ER trial, including prior nephrectomy and PD-L1 status.
Overview of ccRCC and Introduction to the CheckMate 9ER Trial
Toni Choueiri, MD, and Rohit Gosain, MD share their clinical experience treating patients with clear cell renal cell carcinoma (ccRCC) and provide a short summary of previously reported data from the CheckMate 9ER trial.
Choueiri Discusses Updated KEYNOTE-564 Results of Adjuvant Pembrolizumab in RCC
At 2022 ASCO GU, Toni K. Choueiri, MD, explained the data seen in the updated results from the KEYNOTE-564 trial for patients with renal cell carcinoma.
Choueiri Discusses Results of CLEAR Substudy of Lenvatinib Plus Pembrolizumab in RCC
At 2022 ASCO GU, Toni K. Choueiri, MD, discussed the CLEAR study and how East Asian patients with renal cell carcinoma derived similar benefit with lenvatinib plus pembrolizumab as the overall trial population.
Toni Choueiri, MD, on Updated Follow-up Data in RCC at 2021 ASCO
Choueiri detailed combination treatments with follow-up data presented at the 2021 ASCO Annual Meeting.
Future Use of Novel Combinations for Metastatic RCC Treatment
Drs Toni Choueiri and Robert J. Motzer highlight various strategies with novel-based therapies being explored to address limitations surrounding the treatment of metastatic renal cell carcinoma.
Risk Scoring Systems for Metastatic RCC
Considerations regarding the value of using the IMDC (International Metastatic Renal Cell Carcinoma Database Consortium) criteria to risk-stratify patients with metastatic renal cell carcinoma as novel therapies become more widely used.
Implications for Treating Metastatic RCC With TKI/I-O Regimens Upfront
Recommendations regarding how to use novel combinations such as lenvatinib and everolimus, or lenvatinib plus pembrolizumab as frontline therapy for metastatic renal cell carcinoma.
Metastatic RCC: Frontline TKI/IO Safety Data
Treatment-related adverse events to be mindful of when treating patients with metastatic renal cell carcinoma with a TKI/IO regimen, such as lenvatinib and pembrolizumab, in the frontline setting.
The Phase 3 CLEAR Study in Metastatic RCC
Robert J. Motzer, MD, of the Memorial Sloan Kettering Cancer Center, discusses the rationale for studying lenvatinib plus pembrolizumab or everolimus for frontline metastatic renal cell carcinoma treatment and reacts to outcomes of the phase 3 CLEAR study as presented at ASCO GU 2021.
Personal Approaches to Frontline Therapy for Metastatic RCC
Drs Toni Choueiri and Robert J. Motzer discuss factors that impact their decisions for treatment of metastatic renal cell carcinoma in the first-line setting and highlight their go-to regimens.
Frontline Combination Approaches for Metastatic RCC
Toni Choueiri, MD, of the Dana-Farber Cancer Institute, comments on the impact of emerging data presented on newer, novel combination therapies as upfront treatment for patients with metastatic renal cell carcinoma.
Refining Combination Strategies in Metastatic RCC
Drs Toni Choueiri and Robert J. Motzer reflect on recent data supporting the use of TKI/I-O combination regimens for frontline treatment of metastatic renal cell carcinoma.
Toni Choueiri, MD, on What Multidisciplinary Stakeholders Should Know About CheckMate 9ER
In the phase 3 CheckMate 9ER trial, investigators found that nivolumab plus cabozantinib demonstrated improved efficacy and prolonged survival among patients with previously untreated advanced renal cell carcinoma.
Toni Choueiri, MD, on How New Data Impact the Standard of Care for RCC
An expert discusses how new data from the phase 3 CheckMate 9ER trial impact therapy choice in previously untreated advanced renal cell carcinoma.
2 Commerce Drive Cranbury, NJ 08512